公开(公告)号：WO2014037121A1

公开(公告)日：2014-03-13

申请号：PCT/EP2013/002710

申请日：2013-09-10

Applicant: SANOFI

Inventor： CIEREN-PUISEUX, Isabelle ,  ESPOSITO, Virginie ,  FARENC, Christine ,  MARONI, Marylin ,  PERRIN, Laurent

IPC: A61K31/4409 ,  A61K31/496 ,  A61K31/513 ,  A61K31/536 ,  A61K31/675 ,  A61K45/06 ,  A61P31/06 ,  A61P31/18

CPC classification number: A61K31/496 ,  A61K31/4409 ,  A61K31/513 ,  A61K31/536 ,  A61K31/675 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to new doses and regimens of rifapentine and use in the treatment of active tuberculosis disease or tuberculosis infection in patients infected with the human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and treated with a combined antiretroviral combination, in particular with an efavirenz-based combination, and more particularly with a combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.

Abstract translation: 本发明涉及利福喷丁的新剂量和方案，并用于治疗感染人类免疫缺陷病毒（HIV）/获得性免疫缺陷综合征（AIDS）并用抗病毒复合组合治疗的患者的活动性结核病或结核病感染 特别是基于依法韦仑的组合，更具体地说是与依法韦仑，恩曲他滨和替诺福韦地索普西富马酸盐的组合。